An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...

Personalized high-definition transcranial direct current stimulation is linked to improved outcomes in moderate-to-severe ...

A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.

A new study shows that a personalized, precise form of brain stimulation, HD-tDCS, can rapidly ease depression symptoms – and ...

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with ...

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...

The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past ...

It is developing the medication in collaboration with a privately held peer.

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions ...

The biomarker‑guided, randomized, double-blind, placebo-controlled Phase 2b trial was conducted at 58 sites across the US, Canada, and China. The success of this pivotal study led to Fast Track ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...